Adjuvant chemotherapy in localized soft tissue sarcomas: Still not proven

Oncologist

Volumn 14, Issue 10, 2009, Pages 1013-1020

  Blay, Jean Yves ^a,b,c   Le Cesne, Axel ^a,d  

^a CENTRE LÉON BÉRARD   (France)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ET 473; GEMCITABINE; IFOSFAMIDE; IMATINIB; METHOTREXATE; TRABECTEDIN; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; HUMAN; INOPERABLE CANCER; METASTASIS; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SOFT TISSUE SARCOMA; TREATMENT INDICATION; TREATMENT PLANNING; ADJUVANT CHEMOTHERAPY; CANCER STAGING; EVIDENCE BASED MEDICINE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SARCOMA; SOFT TISSUE TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 73349100029     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0126     Document Type: Review

References (55)

1. Clark MA, Fisher C, Judson I et al. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701-711.
2. Toro JR, Travis LB, Wu HJ et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer 2006; 119:2922-2930.
3. Fletcher CD. The evolving classification of soft tissue tumours: An update based on the new WHO classification. Histopathology 2006;48:3-12.
4. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685-694.
5. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007;7:233-245.
6. Coindre JM, Terrier P, Bui NB et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996; 14:869-877.
7. Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: Astudy of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914-1926.
8. Prieur A, Tirode F, Cohen P et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-7283.
9. McArthur G. Dermatofibrosarcoma protuberans: Recent clinical progress. Ann Surg Oncol 2007;14:2876-2886.
10. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
11. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
12. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-3825.
13. Rousseau-Merck MF, Fiette L, Klochendler-Yeivin A et al. Chromosome mechanisms and INI1 inactivation in human and mouse rhabdoid tumors. Cancer Genet Cytogenet 2005;157:127-133.
14. Korf BR. Diagnosis and management of neurofibromatosis type 1. Curr Neurol Neurosci Rep 2001;1:162-167.
15. Sirvent N, Coindre JM, Maire G et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: Utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 2007;31: 1476-1489.
16. Italiano A, Cardot N, Dupré F et al. Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: The "missing link" between lipomas and liposarcomas? Int J Cancer 2007;121:308-315.
17. Idbaih A, Coindre JM, Derré J et al. Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. Lab Invest 2005;85:176-181.
18. Kotiligam D, Lazar AJ, Pollock RE et al. Desmoid tumor: A disease opportune for molecular insights. Histol Histopathol 2008;23:117-126.
19. Casali PG, Jost L, Sleijfer S et al. ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(suppl 2):ii89-ii93.
20. Ray-Coquard I, Thiesse P, Ranchère-Vince D et al. Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. Ann Oncol 2004;15:307-315.
21. Casali PG, Jost L, Reichardt P et al.; ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(suppl 2):ii35-ii38.
22. Ray-Coquard I, Ranchère-Vince D, Thiesse P et al. Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses. Eur J Cancer 2003;39:2021-2025.
23. Demetri GD, Benjamin RS, Blanke CD et al.; NCCN Task Force. NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5(suppl 2):S1-S29; quiz S30.
24. Yang JC, Rosenberg SA. Surgery for adult patients with soft tissue sarcomas. Semin Oncol 1989;16:289-296.
25. Hohenberger P, Wysocki WM. Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: Which treatment to choose? The Oncologist 2008;13:175-186.
26. Issels RD, Lindner LH, Wust P et al. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised trial [abstract 10009]. J Clin Oncol 2007;25(18 suppl):547s.
27. Grünhagen DJ, de Wilt JH, ten Hagen TL et al. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006;3:94-103.
28. Bonvalot S, Laplanche A, Lejeune F et al. Limb salvage with isolated perfusion for soft tissue sarcoma: Could less TNF-alpha be better? Ann Oncol 2005;16:1061-1068.
29. Pisters PW, Harrison LB, Woodruff JM et al. A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. J Clin Oncol 1994;12: 1150-1155.
30. Yang JC, Chang AE, Baker AR et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203.
31. O'Sullivan B, Davis AM, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet 2002;359:2235-2241.
32. Kamada T, Tsujii H, Tsuji H et al.; Working Group for the Bone and Soft Tissue Sarcomas. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol 2002;20:4466-4471.
33. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: A meta-analysis and clinical practice guideline. Sarcoma 2000;4:103-112.
34. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999;17:150-157.
35. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 2002;20:2824-2831.
36. Bay JO, Ray-Coquard I, Fayette J et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis. Int J Cancer 2006;119:706-711.
37. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25:2755-2763.
38. Duffaud F, Bui BN, Penel N et al. A FNCLCC French Sarcoma Group-GETO multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS) [abstract 10511]. J Clin Oncol 2008;26(15 suppl): 555s.
39. Fata F, O'Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034-2037.
40. Penel N, Bui BN, Bay JO. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008;26:5269-5274.
41. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma:Aphase II study from the European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 2009;27:3126-3132.
42. Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133-3140.
43. George S, Merriam P, Maki RG et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154-3160.
44. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005;23:576-584.
45. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study. Lancet Oncol 2007;8:595-602.
46. Demetri GD, Schuetze S, Blay J et al. Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide [abstract 10509]. J Clin Oncol 2009; 27(15 suppl):538s.
47. Stacchiotti S, Tamborini E, Marrari A et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009;15:1096-1104.
48. Gardner K, Judson I, Leahy M et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma [abstract 10523]. J Clin Oncol 2009;27(15 suppl):541s.
49. Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Lancet 1997;350:1647-1654.
50. Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-1247.
51. Woll PJ, van Glabbeke M, Hohenberger P et al. Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft tissue sarcoma: Interim analysis of a randomized phase III trial [abstract 10008]. Proc Am Soc Clin Oncol 2007;25(18 suppl):546s.
52. Blackledge G, van Oosterom A, Mouridsen HT et al. The place of chemotherapy in the management of soft tissue sarcoma: Experiences of the EORTC Soft Tissue and Bone Sarcoma Group. Clin Oncol (R Coll Radiol) 1989;1:106 -109.
53. Le Cesne A, Van Glabbeke M, Woll PJ et al. The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials [abstract 10525]. J Clin Oncol 2008;26(15 suppl): 559s.
54. Schuetze SM, Patel S. Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? The Oncologist 2009;14:1003-1012.
55. Gortzak E, Azzarelli A, Buesa J et al. E.O.R.T.C. Soft Tissue Bone Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group/Canadian Sarcoma Group. A randomised phase II study on neoadjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001;37:1096 -1103.